Lupin recalls over 2000 bottles of antidepressant medication in US
US: Lupin Pharmaceuticals Inc, a US-based subsidiary of Mumbai-headquartered Lupin is recalling over 2000 bottles of an antidepressant medication in the US market, according to the the U.S. Food and Drug Administration (USFDA).
Class II recall is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
This recall is the latest in a series of product withdrawals from various pharmaceutical manufacturers. Similar actions have recently been taken by companies including Sun Pharma, Zydus, and Glenmark in the U.S. market.
Earlier in April, Lupin Healthcare (UK) Limited acquired Renascience Pharma Limited, a UK-based pharmaceutical company and sole supplier of 4 specialty products targeting unmet medical needs in the UK for GBP 12.3 million (appx. 138 crore).
Read also: Lupin UK arm acquires Renascience Pharma for over Rs 138 crore
Lupin Limited is a global pharmaceutical company headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. It has a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally.
